Login / Signup
Mechthild Jonas
ORCID
Publication Activity (10 Years)
Years Active: 2023-2023
Publications (10 Years): 2
Top Topics
Hodgkin Lymphoma
Poor Prognosis
Cell Adhesion
Escherichia Coli
Top Venues
Molecular cancer therapeutics
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Ryan A Heiser
,
Anthony T Cao
,
Weiping Zeng
,
Michelle Ulrich
,
Patrick Younan
,
Martha E Anderson
,
Esther S Trueblood
,
Mechthild Jonas
,
Robert Thurman
,
Che-Leung Law
,
Shyra J Gardai
Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity.
Molecular cancer therapeutics
(2023)
Robert P Lyon
,
Mechthild Jonas
,
Christopher Frantz
,
Esther S Trueblood
,
Roma Yumul
,
Lori Westendorf
,
Christopher J Hale
,
Jackie L Stilwell
,
Narayana Yeddula
,
Katie M Snead
,
Vineet Kumar
,
Gabriela I Patilea-Vrana
,
Kerry Klussman
,
Maureen C Ryan
SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications.
Molecular cancer therapeutics
(2023)